Boothbay Fund Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Boothbay Fund Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-6,100	Closed	-$746K	–	1002
2016 Q4	$746K	Buy	6,100 +2,900	+91%	+$355K	0.17%	141
2016 Q3	$392K	Buy	+3,200	New	+$412K	0.09%	288

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Boothbay Fund Management's ALXN Position: Q3 2021 in Review

Boothbay Fund Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 52,296 shares — an estimated $9.61M sold.

Boothbay Fund Management first reported a position in ALXN in Q3 2016 and held it in 9 quarters. The position peaked at $9.61M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Boothbay Fund Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Boothbay Fund Management sold 52,296 Alexion Pharmaceuticals shares in Q3 2021, an estimated $9.61M.
Boothbay Fund Management first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 9 quarters.
Boothbay Fund Management's Alexion Pharmaceuticals position peaked at $9.61M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Boothbay Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.